S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
S&P 500   3,970.99 (+0.56%)
DOW   32,237.53 (+0.41%)
QQQ   310.89 (+0.37%)
AAPL   160.25 (+0.83%)
MSFT   280.57 (+1.05%)
META   206.01 (+0.85%)
GOOGL   105.44 (-0.15%)
AMZN   98.13 (-0.59%)
TSLA   190.41 (-0.94%)
NVDA   267.79 (-1.52%)
NIO   9.07 (-2.16%)
BABA   86.90 (+0.44%)
AMD   97.95 (-2.32%)
T   18.61 (+0.81%)
F   11.51 (+0.79%)
MU   61.16 (-0.29%)
CGC   1.90 (-0.52%)
GE   91.37 (-0.24%)
DIS   94.08 (-1.83%)
AMC   4.47 (+0.00%)
PFE   40.39 (+0.52%)
PYPL   73.88 (+1.82%)
NFLX   328.39 (+2.50%)
NASDAQ:NVCR

NovoCure - NVCR Competitors

$57.17
+0.36 (+0.63%)
(As of 03/24/2023 12:00 AM ET)
Add
Compare
Today's Range
$56.06
$57.64
50-Day Range
$56.44
$95.09
52-Week Range
$56.06
$120.03
Volume
561,258 shs
Average Volume
1.09 million shs
Market Capitalization
$6.03 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$87.33

NVCR vs. GMED, STVN, INSP, IART, SWAV, MMSI, HAE, ICUI, IRTC, and NARI

Should you be buying NovoCure stock or one of its competitors? The main competitors of NovoCure include Globus Medical (GMED), Stevanato Group (STVN), Inspire Medical Systems (INSP), Integra LifeSciences (IART), Shockwave Medical (SWAV), Merit Medical Systems (MMSI), Haemonetics (HAE), ICU Medical (ICUI), iRhythm Technologies (IRTC), and Inari Medical (NARI). These companies are all part of the "surgical & medical instruments" industry.

NovoCure vs.

Globus Medical (NYSE:GMED) and NovoCure (NASDAQ:NVCR) are both mid-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, media sentiment, community ranking, institutional ownership, valuation, earnings, risk, profitability and dividends.

Globus Medical has a beta of 1.05, indicating that its share price is 5% more volatile than the S&P 500. Comparatively, NovoCure has a beta of 0.83, indicating that its share price is 17% less volatile than the S&P 500.

In the previous week, NovoCure had 1 more articles in the media than Globus Medical. MarketBeat recorded 5 mentions for NovoCure and 4 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.75 beat NovoCure's score of 0.18 indicating that Globus Medical is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Globus Medical
2 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
NovoCure
3 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Globus Medical currently has a consensus price target of $70.91, suggesting a potential upside of 33.44%. NovoCure has a consensus price target of $87.33, suggesting a potential upside of 52.76%. Given NovoCure's higher probable upside, analysts plainly believe NovoCure is more favorable than Globus Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Globus Medical
1 Sell rating(s)
8 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.09
NovoCure
2 Sell rating(s)
2 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.00

Globus Medical received 74 more outperform votes than NovoCure when rated by MarketBeat users. Likewise, 68.86% of users gave Globus Medical an outperform vote while only 65.29% of users gave NovoCure an outperform vote.

CompanyUnderperformOutperform
Globus MedicalOutperform Votes
533
68.86%
Underperform Votes
241
31.14%
NovoCureOutperform Votes
459
65.29%
Underperform Votes
244
34.71%

Globus Medical has higher revenue and earnings than NovoCure. NovoCure is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Globus Medical$759.12 million7.02$190.17 million$1.8628.57
NovoCure$537.84 million11.21-$92.53 million-$0.88-64.97

Globus Medical has a net margin of 18.59% compared to NovoCure's net margin of -17.20%. Globus Medical's return on equity of 11.93% beat NovoCure's return on equity.

Company Net Margins Return on Equity Return on Assets
Globus Medical 18.59% 11.93% 10.62%
NovoCure -17.20% -20.98% -7.91%

74.2% of Globus Medical shares are owned by institutional investors. Comparatively, 78.4% of NovoCure shares are owned by institutional investors. 24.4% of Globus Medical shares are owned by company insiders. Comparatively, 6.2% of NovoCure shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Globus Medical beats NovoCure on 13 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NVCR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NVCR vs. The Competition

MetricNovoCureSurgical & medical instruments IndustryMedical SectorNASDAQ Exchange
Market Cap$6.03B$3.33B$4.33B$5.90B
Dividend YieldN/A3.10%2.39%4.40%
P/E Ratio-64.9761.38108.7912.78
Price / Sales11.2128.323,457.5856.39
Price / CashN/A44.2427.27103.34
Price / Book13.614.264.474.94
Net Income-$92.53M$57.78M$114.81M$190.66M
7 Day Performance0.18%-0.50%-0.81%0.56%
1 Month Performance-25.73%-2.85%-6.60%-5.98%
1 Year Performance-30.41%-26.02%-16.52%-18.84%

NovoCure Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
GMED
Globus Medical
3.0735 of 5 stars
$52.26
-1.7%
$70.91
+35.7%
-23.1%$5.24B$759.12M28.102,600Analyst Downgrade
Positive News
STVN
Stevanato Group
2.4819 of 5 stars
€23.03
-1.6%
€29.00
+25.9%
+31.5%$6.81B$1.04B41.135,260
INSP
Inspire Medical Systems
2.6436 of 5 stars
$241.92
-2.7%
$303.00
+25.2%
-1.0%$7.03B$407.86M-147.51485
IART
Integra LifeSciences
2.0031 of 5 stars
$53.48
-2.4%
$58.17
+8.8%
-13.8%$4.37B$1.56B24.763,722News Coverage
Positive News
SWAV
Shockwave Medical
2.8129 of 5 stars
$210.15
-2.3%
$247.40
+17.7%
+16.4%$7.67B$489.73M36.871,001Insider Selling
MMSI
Merit Medical Systems
1.9455 of 5 stars
$70.52
-0.4%
$76.33
+8.2%
+13.9%$4.04B$1.15B54.256,846
HAE
Haemonetics
2.5611 of 5 stars
$77.31
-3.4%
$101.00
+30.6%
+34.2%$3.90B$1.13B41.792,821
ICUI
ICU Medical
2.2698 of 5 stars
$155.24
-5.7%
$195.00
+25.6%
-33.5%$3.73B$2.28B-49.7614,500
IRTC
iRhythm Technologies
1.6424 of 5 stars
$117.89
-0.5%
$146.36
+24.2%
-14.7%$3.56B$410.92M-30.311,793Analyst Upgrade
NARI
Inari Medical
2.2077 of 5 stars
$61.82
-4.9%
$88.56
+43.2%
-27.0%$3.36B$383.47M-112.401,100Insider Selling
This page (NASDAQ:NVCR) was last updated on 3/24/2023 by MarketBeat.com Staff